Free Trial

InspireMD Q4 2023 Earnings Report

InspireMD logo
$3.19 +0.09 (+2.90%)
As of 02/21/2025 03:59 PM Eastern

InspireMD EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.60

InspireMD Revenue Results

Actual Revenue
$1.76 million
Expected Revenue
$1.65 million
Beat/Miss
Beat by +$110.00 thousand
YoY Revenue Growth
N/A

InspireMD Announcement Details

Quarter
Q4 2023
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

InspireMD Earnings Headlines

InspireMD participates in a conference call with Lake Street
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
InspireMD, NAMSA partner on CGUARDIANS II trial of CGuard Prime
InspireMD (NSPR) Receives a Buy from Lake Street
See More InspireMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email.

About InspireMD

InspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

View InspireMD Profile

More Earnings Resources from MarketBeat